Ophthalmology – Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Basics

Description

Non-arteritic anterior ischemic optic neuropathy (NAION) is an acute ischemic optic neuropathy caused by impaired perfusion of the anterior optic nerve head.

It classically presents with:

• Sudden
• Painless
• Unilateral visual loss
• Optic disc edema
• Relative afferent pupillary defect
• Characteristic visual field loss

NAION is one of the most common acute optic neuropathies in older adults.

Epidemiology

NAION most commonly occurs after age 50.

Reported incidence is approximately:

2–10 cases per 100,000 persons older than 50 years per year

Thousands of new cases occur annually in the United States.

It can also occur in younger adults, particularly when vascular or anatomic risk factors are present.

Risk Factors

Important associated risk factors include:

• Hypertension
• Diabetes mellitus
• Hyperlipidemia
• Obstructive sleep apnea
• Nocturnal hypotension
• Systemic hypoperfusion
• Small-vessel vascular disease
• Smoking
• Migraine in some patients

Anatomic susceptibility also plays a major role.

Medication Associations

Drugs reported in association with NAION include:

• Amiodarone
• Phosphodiesterase-5 inhibitors used for erectile dysfunction

The relationship between erectile dysfunction medications and NAION remains uncertain, and a direct causal relationship has not been definitively established.

Genetics

No consistent Mendelian genetic cause of typical NAION has been established.

Familial cases are uncommon.

Pathophysiology

NAION is believed to result from transient or sustained hypoperfusion of the:

Short posterior ciliary arterial circulation supplying the optic nerve head

This produces ischemia of the retrolaminar/prelaminar optic nerve.

Subsequent:

• Axonal swelling
• Optic disc edema
• Compartment-like crowding

may worsen ischemia in an already anatomically crowded disc.

“Disc at Risk”

The classic structural predisposition is a:

Small, crowded optic nerve head with a very small or absent physiologic cup

This is commonly called the:

“Disc at risk.”

The fellow eye often demonstrates this appearance.

A crowded disc may permit initial axonal swelling to compress adjacent capillaries and worsen ischemic damage.

Systemic Hypoperfusion

NAION is often first noticed on awakening.

This has led to the hypothesis that:

• Physiologic nocturnal blood pressure reduction
• Excessive nighttime antihypertensive effect
• Obstructive sleep apnea

may reduce optic nerve perfusion in susceptible patients.

However, blood pressure management must be individualized because uncontrolled hypertension is itself harmful.

Commonly Associated Conditions

Common associations include:

• Diabetes mellitus
• Hypertension
• Hyperlipidemia
• Obstructive sleep apnea
• Atherosclerotic vascular disease
• Migraine

Diagnosis

NAION is primarily a clinical diagnosis.

The typical patient has:

Acute painless monocular visual loss + swollen optic disc + corresponding visual field defect

History

Typical features include:

• Sudden visual loss in one eye
• Usually painless
• Often noticed on awakening
• Stable or mildly progressive decline over hours to days

Patients may describe:

• Blurred vision
• Dark area in the visual field
• Loss of upper or lower half of vision
• Reduced contrast
• Color desaturation

Pain

Significant orbital pain or pain with eye movement is unusual.

Its presence should raise consideration of:

• Optic neuritis
• Orbital disease
• Other inflammatory optic neuropathies

Visual Acuity

Visual acuity is variable.

Patients may retain relatively good central acuity despite a large visual field defect, or may develop marked central visual loss if the papillomacular fibers are affected.

Pupillary Examination

A unilateral or asymmetric case usually produces:

Relative afferent pupillary defect (RAPD)

Color Vision

Color vision is commonly reduced.

Patients may demonstrate:

• Dyschromatopsia
• Red desaturation
• Reduced color discrimination

The deficit often corresponds roughly with the degree of optic nerve dysfunction.

Visual Field Defect

The classic visual field abnormality is:

Altitudinal field loss

Most often:

• Inferior altitudinal defect

but superior altitudinal loss can also occur.

Other patterns include:

• Arcuate defects
• Central defects
• Nasal steps
• Generalized depression

Optic Disc Appearance

During the acute phase, examination shows:

• Optic disc edema
• Often segmental swelling
• Hyperemic or occasionally pale disc
• Peripapillary splinter or flame hemorrhages

Disc hemorrhages are common and support the diagnosis.

Fellow Eye

The fellow optic nerve commonly shows:

• Small disc
• Minimal or absent cup
• Crowded appearance

This is the classic disc at risk.

Critical Alert – Exclude Giant Cell Arteritis

In an older patient with acute ischemic optic neuropathy, the most important immediate distinction is between:

• NAION
• Arteritic anterior ischemic optic neuropathy (AAION) from giant cell arteritis

AAION is an ophthalmic emergency because the fellow eye can become involved rapidly, causing bilateral severe visual loss.

Symptoms Suggesting Giant Cell Arteritis

Ask specifically about:

• New headache
• Scalp tenderness
• Jaw claudication
• Constitutional symptoms
• Fever
• Weight loss
• Polymyalgia rheumatica symptoms
• Transient visual loss
• Diplopia

Absence of systemic symptoms does not completely exclude GCA.

NAION vs Arteritic AION

Features more suggestive of NAION include:

• Moderately reduced vision
• Hyperemic swollen disc
• Disc hemorrhages
• Crowded fellow disc
• Typical vascular risk factors

Features more suggestive of GCA/AAION include:

• Profound visual loss
• Chalky-white or pallid disc edema
• Older age
• Systemic GCA symptoms
• Markedly elevated inflammatory markers
• Retinal or choroidal ischemia

Laboratory Evaluation

Routine laboratory testing is not necessary for every classic NAION case.

However, in patients in whom GCA is possible—especially those over 50—obtain urgently:

• ESR
• CRP
• CBC with platelet count

If clinical suspicion remains high, management for GCA should not be delayed while waiting for confirmatory testing.

Visual Field Testing

Automated or kinetic perimetry is useful for:

• Documenting the baseline defect
• Monitoring recovery
• Demonstrating altitudinal or arcuate loss

Optical Coherence Tomography

OCT can document:

Acute stage

• RNFL thickening from disc edema

Chronic stage

• RNFL thinning
• Ganglion cell loss
• Optic atrophy

OCT is useful for structural follow-up but does not itself establish the vascular cause.

Fundus Photography

Useful for documenting:

• Optic disc edema
• Peripapillary hemorrhage
• Resolution of swelling
• Subsequent optic atrophy

Fluorescein Angiography

Fluorescein angiography is not usually necessary in straightforward cases.

It may show:

• Delayed disc filling
• Disc leakage

It can be useful when the diagnosis is uncertain or another retinal/choroidal ischemic process is suspected.

Neuroimaging

MRI is not routinely required in classic NAION.

Consider MRI of the brain and orbits when:

• Age is atypical
• Disc edema persists unusually long
• Progressive visual loss continues
• Pain is prominent
• Neurologic abnormalities are present
• A compressive or inflammatory optic neuropathy is suspected

Pathology

Pathologic studies demonstrate:

• Ischemic infarction of the anterior/retrolaminar optic nerve
• Subsequent axonal loss
• Optic nerve atrophy

Differential Diagnosis

Important differential diagnoses include:

• Arteritic AION from giant cell arteritis
• Optic neuritis
• Papillitis
• Papilledema
• Papillophlebitis
• Compressive optic neuropathy
• Infiltrative optic neuropathy
• Amiodarone-associated optic neuropathy
• Diabetic papillopathy
• Central retinal vein occlusion with disc edema

Amiodarone Optic Neuropathy

Amiodarone-associated optic neuropathy may resemble NAION but more often shows:

• Bilateral involvement
• Insidious onset
• Prolonged disc edema
• More gradual visual loss

Treatment

No Proven Vision-Restoring Therapy

At present, there is no established treatment proven to reliably restore vision after acute NAION.

Management therefore focuses on:

• Excluding GCA
• Optimizing systemic risk factors
• Reducing risk to the fellow eye
• Monitoring visual recovery
• Low-vision support when needed

Blood Pressure Management

Hypertension should be appropriately controlled.

However, avoid unnecessary excessive hypotension, particularly at night, in susceptible patients.

Medication timing should be discussed with the patient’s primary physician or cardiologist rather than changed independently.

Diabetes and Lipid Control

Optimize:

• Blood glucose
• HbA1c
• Lipids
• General cardiovascular health

These measures benefit overall vascular health, although they have not been proven to reverse existing NAION.

Obstructive Sleep Apnea

Patients with symptoms or risk factors for obstructive sleep apnea should be evaluated.

Relevant symptoms include:

• Loud snoring
• Witnessed apneas
• Daytime somnolence
• Morning headaches

Treatment of sleep apnea is important for systemic health and may potentially reduce recurrent hypoxic stress.

Aspirin

Aspirin has been investigated for prevention of fellow-eye NAION.

However:

There is no convincing evidence that aspirin reliably prevents NAION in the fellow eye.

Aspirin should be prescribed based on the patient’s general cardiovascular indications rather than specifically as NAION therapy.

Corticosteroids

Systemic corticosteroids have been studied, but evidence has not established them as standard therapy for NAION.

They should not be confused with the urgent high-dose corticosteroid treatment required for arteritic AION due to giant cell arteritis.

Anticoagulation

Anticoagulation has not been proven effective for routine NAION treatment.

It should only be used when there is another established medical indication.

Hyperbaric Oxygen

Hyperbaric oxygen has not demonstrated sufficient benefit to become standard treatment.

Optic Nerve Sheath Decompression

Optic nerve sheath decompression should not be performed for NAION.

Clinical trial evidence demonstrated:

• No visual benefit
• Potential worsening of visual outcomes

This procedure is considered potentially harmful in NAION.

Referral

Patients should be evaluated by an ophthalmologist, preferably:

• Neuro-ophthalmologist

when available.

Medical evaluation should address:

• Hypertension
• Diabetes
• Hyperlipidemia
• Sleep apnea
• Other vascular risk factors

Follow-Up

Typical follow-up may include:

• Early reassessment within 1–2 weeks
• Approximately 1 month
• Approximately 2–3 months

depending on clinical findings.

Course of Disc Edema

Optic disc edema usually resolves over approximately:

6–11 weeks

The disc subsequently develops:

• Segmental pallor
• Diffuse optic atrophy

Persistent swelling well beyond the expected period should prompt reconsideration of the diagnosis.

Patient Monitoring

Follow:

• Visual acuity
• Color vision
• Visual field
• Optic disc appearance
• OCT RNFL and ganglion cell measurements when useful

24-Hour Blood Pressure Monitoring

Ambulatory blood pressure monitoring is not routinely required.

It may be useful in selected patients when there is concern for:

• Excessive nocturnal hypotension
• Medication-related hypotension
• Marked blood pressure variability

Patient Education

Patients should understand that:

• The vision loss is caused by ischemic injury to the optic nerve.
• Recovery is variable.
• The damaged field may remain permanently reduced.
• The fellow eye is also at risk.

They should seek prompt assessment for new visual symptoms in the other eye.

Medication Counseling

Patients should discuss potentially relevant medications with their physicians, particularly:

• Antihypertensives taken at night
• Amiodarone
• PDE-5 inhibitors

Medications should not be stopped without medical supervision.

Prognosis

Visual loss generally becomes stable after the acute phase.

Many patients have persistent visual field defects.

A meaningful spontaneous improvement in visual acuity can occur in a subset of patients over several months.

Fellow-Eye Risk

The fellow eye has a significant but not inevitable risk of developing NAION.

A commonly cited risk is approximately:

15% over 5 years

Risk may be higher in patients with persistent systemic and anatomic risk factors.

Recurrence

Recurrence in the same eye is relatively uncommon because optic atrophy and tissue loss may reduce the crowding that contributed to the original event.

Complications

Potential consequences include:

• Permanent visual field defect
• Persistent reduction in visual acuity
• Dyschromatopsia
• Optic atrophy
• Bilateral visual impairment if the fellow eye later becomes involved

Ophthalmology Pearls

• NAION = sudden painless monocular visual loss + swollen optic disc + altitudinal visual field defect.
• Symptoms are frequently first noticed on awakening.
• The fellow eye often has a small cup-to-disc ratio—the classic “disc at risk.”
• Peripapillary splinter hemorrhages commonly accompany acute disc edema.
• In every older patient with acute ischemic optic neuropathy, exclude giant cell arteritis urgently.
• A pale, chalky swollen optic disc with profound visual loss should raise strong concern for arteritic AION.
• There is currently no proven vision-restoring treatment for NAION.
• Optimize modifiable risks, particularly diabetes, hypertension, hyperlipidemia, and obstructive sleep apnea.
• Avoid unnecessary systemic hypotension, especially excessive nocturnal hypotension.
• Aspirin, anticoagulation, steroids, and hyperbaric oxygen have not been proven to prevent or reverse typical NAION.
• Optic nerve sheath decompression is ineffective and potentially harmful.
• Disc edema usually resolves within several weeks and is followed by optic atrophy.
• Fellow-eye involvement occurs in roughly 15% over 5 years, making long-term risk-factor management important.